Alphabet
Latest statistics and disclosures from Alphabet's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ASTS, PL, ARM, MTSR, RVMD, and represent 63.19% of Alphabet's stock portfolio.
- Added to shares of these 3 stocks: Bridgebio Oncology Therapeut (+$33M), FIG (+$11M), PRME (+$8.3M).
- Started 2 new stock positions in Bridgebio Oncology Therapeut, FIG.
- Reduced shares in these 2 stocks: VERV (-$137M), MTSR (-$62M).
- Sold out of its position in VERV.
- Alphabet was a net seller of stock by $-146M.
- Alphabet has $2.4B in assets under management (AUM), dropping by 12.80%.
- Central Index Key (CIK): 0001652044
Tip: Access up to 7 years of quarterly data
Positions held by Alphabet consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Alphabet
Alphabet holds 37 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ast Spacemobile Com Cl A (ASTS) | 18.2 | $439M | 8.9M | 49.08 |
|
|
| Planet Labs Pbc Com Cl A (PL) | 17.2 | $415M | 32M | 12.98 |
|
|
| Arm Holdings Sponsored Ads (ARM) | 11.5 | $277M | 2.0M | 141.49 |
|
|
| Mestera (MTSR) | 8.2 | $198M | -23% | 3.8M | 52.33 |
|
| Revolution Medicines (RVMD) | 8.0 | $193M | 4.1M | 46.70 |
|
|
| Freshworks Class A Com (FRSH) | 7.9 | $191M | 16M | 11.77 |
|
|
| Tempus Ai Cl A (TEM) | 5.2 | $125M | 1.6M | 80.71 |
|
|
| Gitlab Class A Com (GTLB) | 5.1 | $123M | 2.7M | 45.08 |
|
|
| Uipath Cl A (PATH) | 3.9 | $94M | 7.0M | 13.38 |
|
|
| Prime Medicine (PRME) | 3.8 | $92M | +9% | 17M | 5.54 |
|
| Dex (DXCM) | 2.9 | $70M | 1.0M | 67.29 |
|
|
| Maze Therapeatics (MAZE) | 2.6 | $63M | 2.4M | 25.93 |
|
|
| Bridgebio Oncology Therapeut Com New | 1.4 | $33M | NEW | 2.8M | 11.58 |
|
| Figma Class A Com Stk (FIG) | 0.5 | $11M | NEW | 216k | 51.87 |
|
| Monte Rosa Therapeutics (GLUE) | 0.5 | $11M | 1.5M | 7.41 |
|
|
| Sana Biotechnology (SANA) | 0.4 | $10M | 2.8M | 3.55 |
|
|
| Oscar Health Cl A (OSCR) | 0.4 | $9.1M | 482k | 18.93 |
|
|
| Dianthus Therapeutics (DNTH) | 0.3 | $8.2M | 209k | 39.35 |
|
|
| Relay Therapeutics (RLAY) | 0.3 | $8.2M | 1.6M | 5.22 |
|
|
| Beam Therapeutics (BEAM) | 0.3 | $7.8M | 322k | 24.27 |
|
|
| Vera Therapeutics Cl A (VERA) | 0.3 | $7.0M | 241k | 29.06 |
|
|
| Lyell Immunopharma Com New (LYEL) | 0.2 | $4.8M | 293k | 16.24 |
|
|
| Foghorn Therapeutics (FHTX) | 0.1 | $2.4M | 501k | 4.89 |
|
|
| Genedx Holdings Corp (WGS) | 0.1 | $2.4M | 23k | 107.74 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.1 | $2.1M | 641k | 3.27 |
|
|
| Tscan Therapeutics (TCRX) | 0.1 | $2.0M | 1.1M | 1.82 |
|
|
| Barinthus Biotherapeutics Pl Ads (BRNS) | 0.1 | $1.9M | 1.5M | 1.25 |
|
|
| Spero Therapeutics (SPRO) | 0.1 | $1.7M | 890k | 1.88 |
|
|
| Tenaya Therapeutics (TNYA) | 0.1 | $1.5M | 916k | 1.62 |
|
|
| Hyperfine Com Cl A (HYPR) | 0.1 | $1.3M | 899k | 1.45 |
|
|
| EXACT Sciences Corporation (EXAS) | 0.1 | $1.3M | 23k | 54.71 |
|
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.0 | $1.1M | 698k | 1.63 |
|
|
| Fractyl Health (GUTS) | 0.0 | $1.1M | 663k | 1.59 |
|
|
| Alector (ALEC) | 0.0 | $521k | 176k | 2.96 |
|
|
| Cortexyme (QNCX) | 0.0 | $308k | 189k | 1.63 |
|
|
| Fulcrum Therapeutics (FULC) | 0.0 | $131k | 14k | 9.20 |
|
|
| Repligen Corporation (RGEN) | 0.0 | $51k | 383.00 | 133.67 |
|
Past Filings by Alphabet
SEC 13F filings are viewable for Alphabet going back to 2022
- Alphabet 2025 Q3 filed Nov. 7, 2025
- Alphabet 2025 Q2 filed Aug. 1, 2025
- Alphabet 2025 Q1 filed May 2, 2025
- Alphabet 2024 Q4 filed Feb. 7, 2025
- Alphabet 2024 Q3 filed Nov. 8, 2024
- Alphabet 2024 Q2 filed Aug. 2, 2024
- Alphabet 2024 Q1 filed May 3, 2024
- Alphabet 2023 Q4 filed Feb. 9, 2024
- Alphabet 2023 Q3 filed Nov. 13, 2023
- Alphabet 2023 Q2 filed Aug. 4, 2023
- Alphabet 2023 Q1 filed May 11, 2023
- Alphabet 2022 Q4 filed Feb. 14, 2023
- Alphabet 2022 Q3 filed Nov. 15, 2022
- Alphabet 2013 Q4 filed Nov. 15, 2022
- Alphabet 2014 Q1 filed Nov. 15, 2022
- Alphabet 2014 Q2 filed Nov. 15, 2022